| CIPLA  | 
The Current P/E Ratio of CIPLA  is 22.24.
                
| Share Price | ₹1,501.7 | Oct 31,2025 | 
| Market Cap | ₹121,303.3 Cr | |
| Earnings-TTM | ₹5,453.9 Cr | TTM-Consolidated Results | 
| Price/Earnings | 22.24x | Calculated as Market Cap/Earnings | 
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CIPLA
                    P/E = 
                    Market Capitalization 
                    / Net Income 
                    
                    or, using per-share numbers:
                    
                    P/E = Stock Price / 
                    Earnings Per Share (EPS)
                
               
                                     Current Market Cap [ ₹121,303.3 Cr] as on Oct 31,2025                     
                    (/) Earnings [ ₹5,453.9 Cr] based on TTM-Consolidated Results
                                    
                
                (=) P/E Ratio [ 22.24x ]
            
Thus, for CIPLA , the investors are currently willing to pay 22.24 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CIPLA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CIPLA over the last five years.
Historical PE (Price/Earnings) ratio chart of CIPLA
PE Ratio Performance Analysis for CIPLA
- CIPLA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 27.46x.
- CIPLA 's operated at median p/e ratio of 27.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CIPLA 's p/e ratio peaked in Mar2022 at 32.65x.
- CIPLA 's p/e ratio hit its five-year low in Mar2025 of 22.08x.
How does CIPLA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap | 
|---|---|---|---|
| CIPLA | 5,453.86 | 22.24 | 121,303.3 | 
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 38.94 | 405,452.0 | 
| DIVIS LABORATORIES LTD | 2,306.00 | 77.66 | 179,089.0 | 
| TORRENT PHARMACEUTICALS LTD | 2,002.00 | 60.17 | 120,456.0 | 
| DR REDDYS LABORATORIES LTD | 5,721.40 | 17.47 | 99,965.9 | 
| MANKIND PHARMA LTD | 1,905.51 | 51.60 | 98,333.5 | 
| ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.14 | 98,057.5 | 
| LUPIN LTD | 3,722.18 | 24.10 | 89,722.4 | 
| AUROBINDO PHARMA LTD | 3,417.93 | 19.35 | 66,133.0 | 
| ABBOTT INDIA LTD | 1,452.29 | 42.44 | 61,629.9 | 
| ALKEM LABORATORIES LTD | 2,334.08 | 28.21 | 65,844.5 | 
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CIPLA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio | 
|---|---|
| Min industry PE | 17.47x | 
| Max industry PE | 77.66x | 
| Median industry PE | 28.21x | 
| Average industry PE | 36.67x | 
You may also like the below Video Courses
 
                                     
                                     
                                    